You are here

Article Text

Article menu
Download PDFPDF
Oral Communication 1 – Gynaecological Cancer
Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial
  1. MR Mirza1,
  2. A Dørum2,
  3. B Benigno3,
  4. S Mahner4,
  5. P Bessette5,
  6. IM Bover Barcelo6,
  7. D Berton7,
  8. J Ledermann8,
  9. BJ Rimel9,
  10. J Herrstedt10,
  11. S Lau11,
  12. U Canzler12,
  13. I Palacio Vázquez13,
  14. E Kalbacher14,
  15. J Buscema15,
  16. D Lorusso16,
  17. P Debruyne17,
  18. I Bruchim18,
  19. W Guo19,
  20. D Gupta19,
  21. FA de Jong19 and
  22. UA Matulonis20
  1. 1Nordic Society of Gynaecological Oncology (NGSO) and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  2. 2Nordic Society of Gynaecological Oncology (NSGO), Radiumhospitalet, Oslo, Norway
  3. 3Northside Hospital, Atlanta, GA, USA
  4. 4Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), University Hospital, Ludwig-Maximilians University of Munich, Munich, Germany
  5. 5University of Sherbrooke, Sherbrooke, QC, Canada
  6. 6Hospital Son Llàtzer, Palma, Spain
  7. 7Groupe d’Investigateurs Nationaux pour l’Étude des Cancers Ovariens (GINECO), Institut de Cancérologie de l’Ouest (ICO) Centre René Gauducheau, Saint-Herblain, France
  8. 8National Cancer Research Institute (NCRI), University College London, London, UK
  9. 9Cedars-Sinai Medical Center, West Hollywood, CA, USA
  10. 10University of Copenhagen, Copenhagen, Denmark
  11. 11McGill University, Montreal, QC, Canada
  12. 12TU Dresden, Dresden, Germany
  13. 13Hospital Universitario Central de Asturias, Asturias, Spain
  14. 14CHRU Besançon, Hôpital Jean Minjoz, Besançon, France
  15. 15Arizona Oncology Associates, Tucson, AZ, USA
  16. 16Multicentre Italian Trials in Ovarian Cancer/Mario Negri Gynecologic Oncology (MITO/MaNGO), Fondazione IRCCS National Cancer Institute, Milan, Italy
  17. 17Belgian Gynaecological Oncology Group (BGOG), Kortrijk Cancer Centre, AZ Groeninge, Kortrijk, Belgium
  18. 18Israeli Society of Gynecologic Oncology (ISGO), Hillel Yaffe Medical Center, Hadera, and Technion-Israel Institute of Technology, Haifa, Israel
  19. 19TESARO: A GSK Company, Waltham
  20. 20Dana-Farber Cancer Institute, Boston, MA, USA

Abstract

Introduction/Background Niraparib is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved in the United States and Europe for maintenance treatment of patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer (ROC) following complete or partial response to platinum-based chemotherapy. Here, we present long-term safety data of niraparib, reporting the incidence of treatment-emergent adverse events (TEAEs) among patients in the ENGOT-OV16/NOVA trial.

Methodology ENGOT-OV16/NOVA enrolled 553 patients with ROC who received 2–3 prior lines of platinum-based chemotherapy. Patients were randomised 2:1 to receive niraparib (300 mg once daily) or placebo in independent germline BRCA-mutated (gBRCAmut) or non-gBRCAmut cohorts. We report TEAE incidence monthly for the first 6 months and for months 7–12 combined. After month 12, we report TEAEs to the safety data cutoff of September 2017.

Results Overall, 367 patients received niraparib 300 mg once daily. Dose reductions due to TEAEs were highest in month 1 (34%). In month 5, only 7% of patients required dose reductions. The incidence of any-grade and grade ≥3 haematologic and symptomatic TEAEs decreased each month in the first 6 months and remained low thereafter. Incidence of grade ≥3 thrombocytopenia was highest in month 1 (28%) and decreased to 10% and 5% at months 2 and 3, respectively. Treatment discontinuations due to TEAEs were <5% in each month and time interval measured.

Conclusion The incidence of haematologic and symptomatic TEAEs decreased quickly over the first 3 months and continued to decrease over the duration of the trial. Dose reductions and grade ≥3 thrombocytopenia events were highest in month 1 and decreased rapidly thereafter. Treatment discontinuations due to TEAEs were <5% for all months and time intervals measured. These data demonstrate the importance of appropriate dose selection and support the safe, long-term use of niraparib for maintenance treatment in patients with ROC.

Disclosure AD, IMBB, DB-R, JH, EK, JB, PD, IB, SL: Nothing to disclose WG, SH, FdJ: Employee of Tesaro MRM: Consulting for Clovis, AstraZeneca, Tesaro BB: Honoraria from AstraZeneca, Insys, Funding from Tesaro SM: Grant and Personal Fees from Tesaro, AstraZeneca, Medac, MSD, PharmaMar, Roche, Teva. Personal Fees from Clovis, Sensor Kinesis PB: Site payment for clinical trial conduct from Tesaro JL: Ad Boards and PI for trials with AstraZeneca, Clovis, Pfizer. Ad Boards for Roche. Clinical Trials with MSD/Merck. BJR: Consulting with AstraZeneca, Tesaro, Genentech/Roche. Honoraria from Genentech UC: Honoraria and fees for consulting and Ad boards from Roche, AstraZeneca IPV: Travel and Accomodations from PharmaMar, Roche. Expert Testimony for AstraZeneca. Research Funding from Novartis, Tesaro DL: Ad Board for Tesaro, Clovis, AstraZeneca. Research Support from Clovis. Study Conduction support from Tesaro and PharmaMar UAM: Consulting for Merck KGaA, Clovis, Geneos, Eli Lilly, 2x Oncology

https://doi.org/10.1136/ijgc-2019-ESGO.18

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.